Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Rapid Dose signs product supply agreement with Oakland Health in the UK & EU

Stockhouse Editorial
3 Comments| December 14, 2021

{{labelSign}}  Favorites
{{errorMessage}}

Rapid Dose Therapeutics Corp. (RDT) (CSE.DOSE, OTCMKTS: RDTCF, Forum) – a Canadian biotechnology company revolutionizing drug delivery through innovation – has entered into an agreement with Oakland Health Ltd. (operating as “RD Therapeutics”) to supply QuickStrip™ products to the United Kingdom and the European Union.

Mark Upsdell, CEO of Rapid Dose Therapeutics, commented:

“This strategic partnership supports our business plan of rapid global expansion, bringing our novel QuickStrip™ technology and nutraceutical products into the United Kingdom, with further expansion plans throughout the European Union. It is as a result of our strategic partnerships with leading organizations such as RD Therapeutics that we will achieve broader awareness of our novel delivery technology, as it becomes more widely used, including as an oral delivery system for vaccines.

Full story here.


About Rapid Dose Therapeutics

Rapid Dose Therapeutics Corp. is a publicly-traded Canadian Life Sciences company providing innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. RDT’s service-based annuity contracts drive recurring revenue and facilitate rapid expansion into emerging markets across multiple consumer segments. RDT is committed to continually create innovative solutions for humans, animals, and plants.

New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.

For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.


FULL DISCLOSURE: Rapid Dose Therapeutics Corp. is a client of Stockhouse Publishing.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

Wow, I'm liking this move into the European market. Go RDT!
(1)
December 14, 2021

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today